RecruitingNCT07071051
Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study
Sponsor
Mayo Clinic
Enrollment
15 participants
Start Date
Jul 31, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).
Eligibility
Min Age: 2 YearsMax Age: 22 Years
Inclusion Criteria4
- Age 2-21.5 years
- Confirmed diagnosis of acute lymphoblastic leukemia/lymphoma
- Planned treatment with Cal-PEG
- Informed consent obtained from parents or guardians
Exclusion Criteria6
- Pre-existing coagulation disorders
- Known hypersensitivity to asparaginase products
- Liver failure
- Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)
- Currently pregnant
- Use of systemic blood thinner within 48 hours prior to study blood draw
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07071051